logo
Plus   Neg
Share
Email

Law Office Of Brodsky & Smith Reveals Investigation Of EResearch Technology

Law office of Brodsky & Smith LLC said Saturday it is investigating potential claims against the Board of Directors of eResearchTechnology Inc. (ERT) relating to the proposed acquisition by Genstar Capital.

Under the terms of the transaction, eResearch shareholders would receive only $8.00 in cash for each share of eResearch stock they own. According to Brodsky & Smith, the investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of eResearch for not acting in the shareholders' interests in connection with the sale process to Genstar.

Brodsky & Smith said the transaction may undervalue eResearch as eResearch stock traded at $8.11 as recently as April 3, 2012. In addition, an analyst has set a price target on eResearch stock at $9.00 per share, it added.

Pennsylvania-based eResearch Technology Inc. provides technology-driven services and medical devices primarily in North America, the United Kingdom, and Germany.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT